Novavax lays off 25 percent of workforce
Advertisement
United States: Novavax said on Tuesday it will reduce its global workforce by 25% as the cash-strapped biotech pushes forward with its plans to slash expenses and navigate tepid demand for its COVID-19 vaccines.
The company, which had earlier flagged significant uncertainty around generating revenue for the year, said it expects total annual revenue between $1.4 billion and $1.6 billion, relying on a timely launch of its updated COVID shot.
For the first quarter, it reported a net loss of $293.9 million, compared with a year-ago profit of $203.4 million.
Novavax's coronavirus vaccine is its lone marketed product after 35 years in business and the company is now hoping that its cost controls and a successful trial for its COVID/flu combination vaccine candidate will help it stay afloat.
The layoffs, part of Novavax's ongoing cost-reduction measures, would translate to about 498 jobs out of the 1,992 full-time employees it had as of Feb. 21 according to the company's latest regulatory filings.
The biotech expects the cost-cut plans to help reduce its annual research and commercial expenses by 20% to 25% from last year.
It had $637 million in cash and equivalents at the end of the quarter, compared with $1.3 billion as of Dec. 31.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.